Novo Nordisk’s CagriSema Trails Eli Lilly’s Tirzepatide in Obesity Drug Trial
Novo Nordisk announced on February 23 that its next-generation obesity drug, CagriSema, underperformed against Eli Lilly's tirzepatide in a head-to-head trial, marking a setback in the highly competitive weight-loss drug market.